Trinity BiotechTRIB +3.44%20 Current Ratio is 0.25 as of Dec. 2025, which is 91% below its 10-year median of 2.89. GuruFocus rates TRIB with a GF Score™ of 20/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 96.72% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Trinity Biotech's current ratio for the quarter that ended in Dec. 2025 was 0.25.
Trinity Biotech has a current ratio of 0.25. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Trinity Biotech has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Trinity Biotech's Current Ratio or its related term are showing as below:
TRIB'
s Current Ratio Range Over the Past 10 Years
Min: 0.25 Med: 2.89 Max: 5.3
Current: 0.25
During the past 13 years, Trinity Biotech's highest Current Ratio was 5.30. The lowest was 0.25. And the median was 2.89.
TRIB's Current Ratio is ranked worse than 96.72% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs TRIB: 0.25
Trinity Biotech (NAS:TRIB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Trinity Biotech Current Ratio Related Terms
Trinity Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Trinity Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a Current Ratio of 0.25 as of Dec. 2025. This is 91% below median its historical median of 2.89. Over the past decade, Trinity Biotech's Current Ratio has ranged from 0.25 to 5.30. According to the industry distribution chart, Trinity Biotech ranks #826 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 96.7%.
Is Trinity Biotech's Current Ratio too high?
Trinity Biotech's current Current Ratio of 0.25 is 91% below median its 10-year median of 2.89. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 5.30. The Medical Devices & Instruments industry median Current Ratio is 2.49. Trinity Biotech's value of 0.25 is 89.9% below this industry median. Based on the distribution chart, Trinity Biotech ranks #826 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Current Ratio compare to PMI and NXL?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #826 out of 854 companies for Current Ratio. This places Trinity Biotech in the lower half of its industry. The industry median Current Ratio is 2.49. Trinity Biotech's value of 0.25 is 89.9% below this benchmark. Historically, Trinity Biotech's own Current Ratio has ranged from 0.25 to 5.30 over the past decade. While the company's 10-year median is 2.89 vs. the industry median of 2.49, Trinity Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trinity Biotech's current Current Ratio of 0.25 is 89.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current Current Ratio is 0.25, which is 91% below median its own 10-year median of 2.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.36 — trading 51.1% below its estimated fair value. The current Current Ratio is 0.25, which is 91% below median its 10-year median of 2.89 and 89.9% below the Medical Devices & Instruments industry median of 2.49. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Current Ratio is 0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.36 is trading 51.1% below its estimated GF Value™ of $0.73.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Current Ratio: 0.25 (91% below median its 10-year median of 2.89)
GF Value™: $0.73 vs. price of $0.36 (51.1% below fair value)
Industry Position: 89.9% below the Medical Devices & Instruments median (#826 of 854)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score
Get the complete analysis for TRIB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
